Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.
Vitolo
Umberto
U
Department of Oncology and Hematology, Hematology 2, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy. uvitolo@molinette.piemonte.it
Barosi
Giovanni
G
Fanti
Stefano
S
Gianni
Alessandro M
AM
Martelli
Maurizio
M
Petrini
Mario
M
Zinzani
Pier Luigi
PL
Tura
Sante
S
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D006405:Hematology; D006801:Humans; D007558:Italy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008558:Melphalan / Q000627:therapeutic use; D011034:Podophyllotoxin / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012008:Recurrence; D012955:Societies, Medical; D013997:Time Factors
D000911:Antibodies, Monoclonal; D003561:Cytarabine; C422802:ibritumomab tiuxetan; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine